Elsulfavirine: First Global Approval
- 219 Downloads
Elsulfavirine (Elpida®) is a new-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed by Viriom for the treatment and prevention of human immunodeficiency virus (HIV) infections. It is the prodrug of the active compound VM-1500A, a small molecule selective NNRTI, which prevents HIV replication. In June 2017, elsulfavirine received its first global approval in Russia for the treatment of HIV-1 infections in combination with other antiretroviral medicines. Other formulations of this drug are also being evaluated in preclinical and phase II studies for the treatment of HIV infections and/or pre-exposure and post-exposure prophylaxis. This article summarizes the milestones in the development of elsulfavirine leading to this first approval in HIV-1 treatment.
- 1.Viriom Inc. Viriom obtains first market approval of elsulfavirine (Elpida®) for treatment of HIV-1 infection in Russia [media release]. 2017. https://www.viriom.com. Accessed 19 Sep 2017.
- 2.Viriom Inc. HIV/AIDS: definition, prevention, treatment, diagnosis, causes. 2017. https://www.viriom.com/hiv/. Accessed 19 Sep 2017.
- 4.Viriom Inc. Elpida (elsulfavirine) capsules: Russian prescribing information. 2017. http://arvt.ru/drugs/NNRTI/Elsulfavirine.html. Accessed 19 Sep 17.
- 5.Viriom Inc. Viriom pipeline. 2017. https://www.viriom.com/pipeline/. Accessed 19 Sep 2017.
- 6.Viriom Inc. Viriom announces receipt of funding from the Skolkovo Foundation, ChemRar and Torrey Pines Investment to develop Elpida(Rm), a novel preventive and long- acting treatment of HIV/AIDS [media release]. 2016. http://www.viriom.com. Accessed 19 Sep 2017.
- 7.Viriom Inc. Viriom expands global licensing agreement with Roche for innovative compound development for HIV treatment [media release]. 2013. http://www.viriom.com. Accessed 19 Sep 2017.
- 8.Viriom Inc. Roche and Viriom sign license agreement for innovative drugs against HIV [media release]. 2009. https://www.viriom.com. Accessed 19 Sep 2017.
- 9.ChemDiv Inc. Viriom selects ChemDiv to develop HIV program [media release]. 2009. http://www.chemdiv.com. Accessed 19 Sep 2017.
- 10.Kravchenko A, Orlova-Morozova E, Nagimova F, et al. Safety and antiviral effect of elpida (VM-1500), a novel NNRTI (+truvada) in treatment-naïve HIV-1 infected patients [poster PE7/4]. In: 15th European AIDS Conference. 2015.Google Scholar
- 11.Murphy RL, Kravchenko A, Orlova-Morozova E, et al. Elsulfavirine as compared to efavirenz in combination with TDF/FTC: 48-week study [abstract no. 452LB plus poster 2637]. In: Conference on Retroviruses and Opportunistic Infections (CROI). 2017.Google Scholar
- 12.US Department of Health and Human Services. AIDSinfo: VM-1500. 2017. https://aidsinfo.nih.gov/drugs/582/vm-1500/0/patient. Accessed 19 Sep 2017.
- 13.Viriom Inc. Research and development of innovative formulations of the Russian drug (new-generation NNRTI) and new treatment regimens to improve compliance and treatment efficacy for patients with HIV infection [presentation]. In: Conference Biotech RusFrance 2016: new Russian-French cooperation opportunities in biotechnology. 2016.Google Scholar
- 14.Ratanasuwan W, Werarak P, Koryakova A, et al. Pharmacokinetics of VM-1500 20 mg and 40 mg in healthy and HIV-infected patients [abstract no. LBPE20 plus poster]. In: 20th International AIDS Conference. 2014.Google Scholar
- 15.Bichko V, Rogovoy B, Koryakova A, et al. Pre-clinical pharmacokinetics of elsulfavirine/VM1500A long acting injectable formulations [abstract no. WEPEA0190 plus poster]. In: 9th IAS Conference on HIV Science [IAS2017]. 2017.Google Scholar
- 16.Kravchenko A, Orlova-Morozova E, Shimonova T, et al. The efficacy and safety of elpivirine as part of a 24–48-week antiretroviral therapy regimen versus an efavirenz-containing regimen. Epidemiol Infect Dis. 2016;5:73–80.Google Scholar
- 17.Ratanasuwan W, Werarak P, Murphy RL, et al. A randomized, placebo-controlled, double-blind study of VM-1500 in HIV-naive patients [abstract no. 544LB]. Top Antivir Med. 2014;22(e1):262–3.Google Scholar